Lykos still plotting path to approval for rejected MDMA therapy after 'productive' FDA meeting

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for post-traumatic stress disorder (PTSD). But the biotech has reminded us this week that it hasn’t given up hope yet.